Tilmicosin is a novel macrolide antibiotic developed for exclusive use in veterinary medicine. Tilmicosin has been approved as a feed premix to control porcine respiratory disease associated with Pasteurella multocida and Actinobacillus pleuropneumoniae. The development of antimicrobial susceptibility testing guidelines for tilmicosin was predicated on the relationship of clinical efficacy studies that demonstrated a favorable therapeutic outcome, on pharmacokinetic data, and on in vitro test data, as recommended by the National Committee for Clinical Laboratory Standards (NCCLS). The approved breakpoints for the minimum inhibitory concentration dilution testing for both species are resistant, Ն32 g/ml, and susceptible, Յ16 g/ml. The zone of inhibition interpretive criteria for disk diffusion testing with a 15-g tilmicosin disk are resistant, Յ10 mm, and susceptible, Ն11mm.
Tilmicosin (20-deoxo-20-(3,5-dimethylpiperidin-1yl)desmycosin) is a semisynthetic macrolide antibiotic produced by chemical modification of a tylosin-related compound. 3 Tilmicosin, used exclusively in veterinary medicine, has been approved for use in the control and treatment of respiratory diseases in farm animals. 12 The antimicrobial spectrum of tilmicosin includes Gram-positive bacteria, mycoplasma, and some Gramnegative bacteria such as Fusobacterium necrophorum, Actinobacillus pleuropneumoniae, Pasteurella multocida, and Mannheimia (Pasteurella) haemolytica. 4, 10, 23, 24 Many clinical trials have demonstrated the efficacy of tilmicosin (Micotil) against bovine respiratory disease (BRD). 6, 9, 13, 15, 17, 29 A product that controls swine respiratory disease (SRD) would be of value to the swine production industry by reducing the loss due to morbidity and mortality and minimizing the use of injectable antibiotics that can result in carcass trim. Numerous clinical field studies have demonstrated that tilmicosin, as Pulmotil, controls SRD. 14, 16, 18 The potential application for an injectable formulation of tilmicosin for the treatment or control of porcine respiratory disease was contraindicated due to a low margin of safety. 11 Reports on the pharmacokinetics of tilmicosin in swine demonstrated that lung homogenate concentrations exceeded serum concentrations (Thomson TD, et al., Proc 13th Cong Int Pig Vet Soc, Bangkok, Thailand, 1994, p. 330). However, both these concentra-tions were below the minimal inhibitory concentration (MIC) of 8 g/ml for P. multocida and A. pleuropneumoniae. 25 Interestingly, there are several other important parameters that contribute to in vivo antibacterial efficacy. Like other macrolide antibiotics, tilmicosin is concentrated within the phagocyte and is transported to the site of infection. 26 Additionally, there is evidence that tilmicosin can augment phagocyte antibacterial enzyme concentrations. 26 Even at several dilutions below the MIC, tilmicosin exhibits a strong postantibiotic effect on bacteria. 5, 22 The efficient application of Pulmotil, by means of the Veterinary Feed Directive procedure, is dependent on a collaborative relationship between the veterinary diagnostic laboratory, the attending veterinarian, the producer, and the feedmill. To assist the veterinarian, the laboratory must perform antimicrobial susceptibility testing properly and provide consistent interpretations of the results. The Veterinary Antimicrobial Susceptibility Testing (VAST) subcommittee of the National Committee for Clinical Laboratory Standards (NCCLS) has developed specific veterinary guidelines for the interpretations of in vitro susceptibility tests for animal pathogens. 20 The objective of the present study was to relate the in vitro susceptibility data for A. pleuropneumoniae and P. multocida to pharmacokineticpharmacodynamic parameters and clinical efficacy to establish MIC breakpoints and disk diffusion interpretive criteria for tilmicosin used in swine.
Materials and methods
Microorganisms. Clinical isolates and reference collections of swine-origin P. multocida (n ϭ 163) were collected within the last 10 years from various geographic regions in the United States (Indiana, Missouri, California, Georgia, Iowa). Clinical isolates and reference collections of A. pleuropneumoniae (n ϭ 134) were collected within the last 10 years from various geographic regions in North America (Kansas, Iowa, Canada [Montreal], Missouri, California, Georgia, Illinois, Ohio, Indiana, Nebraska). The reference collection included 12 known serotypes of swine-origin A. pleuropneumoniae. These swine isolates comprised the population of microorganisms used for evaluation. A minimum of 100-300 isolates is recommended by the NCCLS to develop the interpretive criteria for a single genus or species. 19 The isolates were randomly collected with no special attempts to select for specific antimicrobial resistance patterns or mechanisms. Actinobacillus pleuropneumoniae reference strain ATCC 27088 was used throughout the trial for quality control. Pasteurella multocida reference strains used throughout the trial for quality control were ATCC 43137, ATCC 12945, ATCC 12948, in addition to S. aureus ATCC 29213 (dilution test) and ATCC 25923 (disk diffusion test).
Antimicrobial susceptibility test methodology. Tilmicosin and erythromycin MICs were determined according to the procedures detailed by the NCCLS. 20 The antimicrobial susceptibility tests were conducted in three different laboratories: Elanco Animal Health, Greenfield, Indiana; Iowa State University (Dr. L. Hoffman); and Purdue University (Dr. C. C. Wu). The broth microdilution technique was performed in custom-prepared 96-well Sensititre plates a using cationadjusted Mueller-Hinton broth b for P. multocida and veterinary fastidious medium for A. pleuropneumoniae made in each laboratory. 20 The disk diffusion method employed Mueller-Hinton II agar with 5% sheep red blood b for P. multocida isolates, while chocolate agar b was utilized for A. pleuropneumoniae isolates. Disk diffusion tests were conducted following the NCCLS recommendations. 20 Disks contained 15 g tilmicosin b and were placed on the appropriate media. Quality control guidelines for tilmicosin susceptibility have been previously described 28 and updated. 20 The update consisted of A. pleuropneumoniae-tilmicosin-specific quality control ranges.
Data analysis. The analysis of the scattergram data for determining the relationship between MICs and zone size was performed using formulas and guidelines previously described. 2, 19 Results Two scattergrams to illustrate the relationship between MIC and zone size for a population of 134 A. pleuropneumoniae ( Fig. 1 ) and 163 P. multocida isolates ( Fig. 2 ) of porcine origin were constructed. The isolates used in these populations were clinical trial isolates, reference strains, and diagnostic isolates. The quality control results for tilmicosin were within range. The modal MIC is 8 g/ml for each genus, with a wide range of zone of inhibition values. The uneven distribution of points over the narrow range of MIC values precluded regression analysis, making error-rate bounding the preferred statistic. 19, 30 Because the VAST decided to forego an intermediate category of interpretation (see Discussion), the partitioning of the isolates into resistant (MIC Ն 32 g/ml; Յ10 mm) and susceptible (MIC Յ 16 g/ml; Ն11 mm) categories minimized the major and minor error rates to 0 (calculations not shown 2, 19 ).
Tilmicosin and erythromycin are both members of the macrolide class of antibiotics. As specified in the NCCLS guidelines, comparative studies within an antibiotic class are necessary. 19 Therefore, 162 P. multocida isolates and 129 A. pleuropneumoniae isolates were tested by broth microdilution against erythromycin, with the results plotted against tilmicosin MICs in a scattergram (Figs. 3, 4) . A regression analysis was not possible because of the clustered distribution of MIC values. Therefore, isolates were compared based on the linear isolate pairing MIC ratio of erythromycin:tilmicosin. 7 Comparable MICs were observed for 89.6% of the P. multocida isolates and 70.5% A. pleuropneumoniae isolates. Actinobacillus pleuropneumoniae isolates that did not demonstrate comparable MIC had MICs that were Ն2 dilutions less than those obtained using tilmicosin. Figures 5 and 6 provide a comparison of the zones of inhibition for erythromycin with those of tilmicosin. For 60 P. multocida isolates, the observed trend was for the erythromycin zones to be 1-8 mm larger and on average 4 mm greater than the corresponding tilmicosin zones. For 77 A. pleuropneumoniae isolates, the observed trend was for the erythromycin zones to be 1-5 mm larger and on av-erage 3 mm greater than the corresponding tilmicosin zones.
Discussion
The development of animal species-bacterial pathogen breakpoints and zone interpretive criteria is based on 3 components: 1) therapeutic outcome of treatment, 2) pharmacokinetics-pharmacodynamics, and 3) in vitro susceptibility testing as outlined in the NCCLS M37-A. 19 This document can be used as a guide with specific allowances for unique differences in livestock evaluation, as opposed to human patient population, to establish interpretive criteria.
Tilmicosin phosphate (Pulmotil) is indicated for the control of bacterial pneumonia in growing swine caused by P. multocida and/or A. pleuropneumoniae. The clinical evaluation of tilmicosin phosphate was initiated by testing various doses incorporated into the feed. The effective dosage range of tilmicosin for the control of swine respiratory disease associated with P. multocida and A. pleuropneumoniae was established in 4 disease-challenge trials. In these trials, tilmicosin phosphate was mixed in feed at 100, 200, 300 and 400 ppm (a nonmedicated control group was included) and fed to pigs for 7 days before being challenged by the seeder pig model, as previously described. 14, 18 Tilmicosin phosphate fed at concentrations of 100-400 ppm significantly improved clinical impression score, decreased the daily rectal temperature, decreased the pneumonic lung involvement, and increased weight gain compared with the nonmedicated control. For the same variables, the doses ranging from 200 to 400 ppm were more effective than the 100-ppm dose. The efficacy of a 200-and 400-ppm dose was tested in 12 clinical field trials in the United States. 16 Compared with nonmedicated pigs, those receiving tilmicosin had no mortality, significantly improved weight gain and feed conversion, and decreased clinical impression scores when pneumonia was present in the herd. In this study, the 400-ppm dose of tilmicosin did not provide any additional improvement over the 200-ppm dose; however, the challenge conditions of naturally acquired pneumonia were moderate.
Clinical studies outside the United States also have demonstrated a favorable therapeutic outcome. In a European tilmicosin (Pulmotil) trial, a dose of 200-400 ppm significantly reduced the incidence of pneumonia and clinical illness and increased the weight gain compared with nonmedicated controls (Langley et al., Proc 13th Cong Int Pig Vet Soc, Bangkok, Thailand, 1994, p. 331). Additionally, tilmicosin at a dose of 400 ppm was more effective than oxytetracycline (400 ppm) as judged by lower incidence of acute pneumonia, less dyspnea, lower temperatures, and less use of injectable therapy. Together these studies demonstrate that feeding tilmicosin at a dose of 200-400 ppm for 21 days, beginning 7 days prior to an anticipated disease outbreak, resulted in a favorable therapeutic outcome in the control of porcine respiratory disease. These studies established the first part of the necessary foundation for interpretive criteria development.
The pharmacokinetics and pharmacodynamics of tilmicosin in swine have been studied using 200-and 400-ppm doses in feed. Data on tilmicosin fed to healthy pigs showed that serum tilmicosin concentration was detectable in only 3 of 20 pigs fed the 200ppm tilmicosin dose while those dosed with the 400ppm tilmicosin level never exceeded a mean level of 0.23 g/ml. In contrast, tilmicosin lung concentrations peaked between 2 and 4 days postadministration with a concentration of 1.11 g/g for the 200-ppm dose and 2.29 g/g for the 400-ppm dose (Thomson TD, et al., Proc 13th Cong Int Pig Vet Soc, Bangkok, Thailand, 1994, p. 330). Although the efficacy of tilmicosin has been demonstrated in clinical trials, the concentration of tilmicosin in lung tissue at both the 200-and 400ppm doses (approximately 1-2 g/g) was below the modal tilmicosin MIC (8 g/ml) for P. multocida and A. pleuropneumoniae isolates.
Three mechanisms may offer an explanation for tilmicosin efficacy despite the inability to attain the target MIC in vivo. First, tilmicosin has an extremely strong postantibiotic effect (PAE) on P. multocida and A. pleuropneumoniae even at 1/8 of the MIC. 5 The strong PAE of tilmicosin on these respiratory pathogens may hinder disease progression by allowing the host response to eliminate the bacteria before the establishment of disease. Specifically, the weakened population of bacteria can be more readily eliminated by local phagocytes. Second, alveolar macrophages (the resident phagocyte of the respiratory tract) can effectively concentrate tilmicosin intracellularly. An in vitro study, using primary swine alveolar macrophages, found that tilmicosin was concentrated in proportion to the amount of drug in the culture medium, with the intracellular to extracellular ratio in the 10 g/ml medium being 51.76 and the 20 g/ml medium being 75.04 after 24 hours incubation (Blais J, et al., Proc 13th Int Cong Pig Vet Soc, Bangkok, Thailand, 1994, p. 331). Another study demonstrated that monocytes and neutrophils also accumulate tilmicosin, with uptake in neutrophils being the greatest. 26 The intracellular tilmicosin was localized in the lysosomes of the phagocytes, which may augment the ability of the phagocyte to kill ingested bacteria within the phagolysosome. This phenomenon is also present in vivo, where tilmicosin concentrations of 7.2-12.2 g/ml were measured in alveolar macrophages after pigs were fed 400 ppm tilmicosin for 10 days (Stoker J, et al., Proc 14th Cong Int Pig Vet Soc, Bologna, Italy, 1996, p. 656). Because leukocytes migrate to the site of infection, intracellular accumulation of tilmicosin within leukocytes may provide a unique mechanism for delivering antibiotic to the site of infection, similar to that proposed for azithromycin. 8 In vitro work demonstrated the efflux of 60 and 22% of intracellular tilmicosin after 30 minutes from neutrophils and alveolar macrophages, respectively. 26 After 24 hours, these percentages increased to 70 and 63%, respectively. Thus, the concentration of antibiotic in the local microenvironment of the lung could exceed the target pathogen's MIC. Third, tilmicosin has been shown to augment the production of phagocyte lysosomal enzymes. 26 Increased production of lysosomal enzymes, acid phosphatase, and lysozyme by tilmicosin may augment the bactericidal activity of the phagocyte, thus increasing resistance to disease. These mechanisms (the direct antibacterial effect, the subinhibitory effects on bacteria, and the stimulatory effects on host defenses) could help provide an explanation for the observed clinical efficacy of oral tilmicosin in the control of field outbreaks of bacterial pneumonia in swine. The data available on the pharmacokinetics-pharmacodynamics of tilmicosin in the porcine lung provide the second part of the information needed to establish interpretive criteria.
The third component for the proposed guidelines is antimicrobial susceptibility testing. The initial approach to scattergram evaluation is to use a population of isolates, regardless of the specific site of bodily origin, as described in the NCCLS M37-A. 19 The population of isolates obtained for this study was comprised of clinical laboratory isolates from swine with SRD (lung specimens) and reference collections. In field tests that demonstrated clinical efficacy, 16 P. multocida (n ϭ 19) and A. pleuropneumoniae (n ϭ 51) isolated from pigs prior to medication had tilmicosin MIC ranges of 2-16 g/ml and 4-16 g/ml, respectively. These observed MICs corresponded well with the approved breakpoints of tilmicosin established for P. multocida and A. pleuropneumoniae. These MIC values for A. pleuropneumoniae and P. multocida were similar to those reported by others. 1, 10, 23, 25 Combining the available data on therapeutic outcome, pharmacokinetics-pharmacodynamics, and antimicrobial susceptibility testing provided a rational basis for defining the MIC breakpoints and zone interpretive criteria. Tilmicosin fed at the 200-or 400ppm dose resulted in an acceptable therapeutic outcome. The pharmacokinetic data for both doses demonstrated a peak whole-lung homogenate mean tilmicosin concentration well below the MIC. The MIC frequency results (Figs. 1, 2) showed that 100% of the A. pleuropneumoniae and 86% of the P. multocida isolates had MICs above 1 g/ml and therefore would not be predicted to be fully susceptible. Thus, reliance on clinical studies (where all the isolates' MICs were Յ16 g/ml) was used to establish the Յ16 g/ml susceptible breakpoint. Isolates with an MIC Ն 32 g/ml were therefore deemed resistant by consensus decision. An intermediate category was not considered necessary because of the magnitude of the concentrations being tested and the lack of data on which to make such a category. Comparison of the proposed breakpoints and zone diameter interpretive criteria for tilmicosin against P. multocida of porcine origin to the NCCLS-approved breakpoints and zone interpretive criteria for tilmicosin against Pasteurella and Mannheimia species of bovine origin is therefore slightly different between the species because of different pharmacokinetics where tilmicosin is concentrated in bovine lung tissue to a far greater extent than in swine lung tissue. 27 Corresponding zone interpretive criteria for disk diffusion testing was developed in association with the MIC test. The ideal minimum recommended zone size for susceptibility is 15-25 mm. 19 However, unlike the situation with bovine pasteurella, the scattergram distributions for both swine bacterial genera did not allow compliance with this concept. (The development of a disk with a higher concentration of tilmicosin was not considered feasible.) Zones of inhibition Ն11 mm were considered susceptible and those Յ10 mm were termed resistant when separated against the MIC values. Elimination of the intermediate category minimized the calculation of very major errors and major errors to zero, which complies with the allowable values of Յ1.5 and Յ3%, respectively.
Studies comparing the MIC and zone of inhibition between tilmicosin and erythromycin were performed. The MIC values of erythromycin and tilmicosin against A. pleuropneumoniae were 90% similar (within one log 2 dilution), while approximately 80% of P. multocida isolates were similar. In both instances, there was a tendency for larger zone sizes and lower MICs to be observed with erythromycin than for tilmicosin.
Although similar, the interpretive criteria for the 2 macrolide antibiotics are different. Erythromycin breakpoints in M31A (adapted from M100-S11 21 ) ''for organisms other than streptococci'' are resistant at Ն8 g/ml compared with Ն32 g/ml for tilmicosin against A. pleuropneumoniae and P. multocida. Erythromycinsusceptible breakpoints in M31A (adapted from M100-S11) ''for organisms other than streptococci'' are Յ0.5 g/ml, with 1-4 g/ml as intermediate, whereas for tilmicosin for A. pleuropneumoniae and P. multocida, isolates are susceptible with an MIC of Յ16 g/ml. Zone diameter interpretive criteria also are markedly different for the 2 macrolides, with erythromycin susceptible at Ն23 mm (''for organisms other than streptococci'') versus Ն11 mm for tilmicosin and Յ13 mm for resistance for erythromycin versus Յ10 mm for tilmicosin.
The breakpoint and zone interpretive criteria for tilmicosin were based on swine therapeutic outcome data, swine pharmacokinetic-pharmacodynamic studies, and in vitro susceptibility testing. This information will allow the veterinary diagnostic laboratory to provide information on susceptibility test outcomes to veterinarians and support the rational use of tilmicosin in the control of SRD.
